Today: 10 June 2026
Marvell Technology targets AI data-center bottlenecks with new 1.6T “pluggable” optics
5 March 2026
1 min read

Marvell Technology targets AI data-center bottlenecks with new 1.6T “pluggable” optics

Santa Clara, Calif., March 5, 2026, 11:53 (PST)

Marvell Technology, Inc. (MRVL.O) said on Thursday it has built a 1.6-terabit “pluggable” optical module and 2-nanometer coherent chips with built-in security, aiming at the fiber links that connect AI-heavy cloud data centers. The company plans to show the products at OFC 2026 in Los Angeles on March 15–19. Business Wire

The move lands as cloud operators add compute in chunks and then discover the hard part: shifting data fast between clusters, racks and sites. More AI work is spread out, and that pushes up traffic between data centers, not just inside them.

Pluggables are optical transceivers that slot into a router or switch, cutting out some separate transport gear. ZR and ZR+ refer to industry specifications for coherent optics used for data-center interconnects, while a coherent DSP is the chip that does the heavy signal processing to move bits reliably over fiber. MACsec, short for media access control security, is a link-layer method used to encrypt Ethernet traffic.

“Meeting the global needs of AI-driven data centers requires proven, large-scale manufacturing strength,” said Russ Esmacher, senior vice president and general manager for data center interconnect at Marvell. Scott Wilkinson, lead analyst at Cignal AI, said: “Maintaining leadership requires power efficiency, critical features and high-volume manufacturability.” Marvell Technology, Inc.

Marvell said its COLORZ 1600 module is powered by an Electra coherent DSP built on a 2-nm process, while a Libra DSP will support an updated COLORZ 800 pluggable. The company expects to begin sampling Electra, Libra and the corresponding COLORZ modules in the second half of 2026.

Marvell shares were down about 2.5% at $76.12 in late morning trading, valuing the company at roughly $80.8 billion.

The coherent-pluggable field is crowded, with rivals including Cisco Systems’ Acacia unit, which sells 800G ZR/ZR+ coherent optics designed to push 800G from a router or switch port over data-center links. That puts pressure on vendors to keep lifting speeds while trimming power draw.

Marvell sells data infrastructure semiconductors across the data center and network edge, spanning networking, storage and carrier markets, according to its company profile. Matthew Murphy is its chief executive.

Investors will turn to earnings later on Thursday, when Marvell is due to hold a conference call at 4:45 p.m. ET to discuss its latest results. The company’s commentary on AI-driven networking demand will likely matter as much as the numbers.

But the new optics and chips are not expected to start reaching customers for sampling until the back half of the year, and ramps at leading-edge nodes can slip. If cloud buyers delay upgrades, or lean harder on competing modules and in-house designs, the pricing and volume story could look different by the time the parts are ready.

Stock Market Today

  • Outlook Therapeutics Shares Jump 26% on FDA Fast-Track Review for Lytenava
    June 10, 2026, 5:57 PM EDT. Outlook Therapeutics shares surged about 26% to $0.89 on heavy volume as the FDA designated its Lytenava (ONS-5010) resubmission a Class 1 review, triggering a faster 60-day decision timeline. The drug targets wet age-related macular degeneration (wet AMD), a vision-impairing condition. The FDA's ruling follows an appeal overturning earlier efficacy concerns and reclassifies the application for expedited review. Despite the stock's gains, Outlook remains below the $1 Nasdaq compliance threshold, raising concerns over dilution. CEO Bob Jahr called the update a testament to the company's strong application. Lytenava, an anti-VEGF therapy, would compete with Roche and Regeneron products in the lucrative U.S. wet AMD market.

Latest articles

Parabilis Medicines (PBLS) soars 58% after $670 million IPO beats range

Parabilis Medicines (PBLS) soars 58% after $670 million IPO beats range

10 June 2026
Parabilis Medicines soared 58% above its $20 IPO price to close at $31.60 in its Nasdaq debut after raising a record $670 million, reflecting strong investor demand for its Helicon drug platform ahead of a pivotal Phase 3 desmoid tumor trial planned for 2027; Regeneron’s $75 million private placement added credibility.
Joby Aviation Shares Slip After CFO Files to Sell Stock

Joby Aviation Shares Slip After CFO Files to Sell Stock

10 June 2026
Joby Aviation fell 4.47% to $8.86 after CFO Rodrigo Brumana disclosed selling 78,489 shares under a prearranged 10b5-1 plan, with no new certification or commercial-launch updates, leaving investors focused on regulatory progress and cash burn as the key catalysts for the stock.
YY Group Shares Spike as Humanoid Robot Plans Unveiled

YY Group Shares Spike as Humanoid Robot Plans Unveiled

10 June 2026
YY Group Holding shares surged to $0.165 on heavy volume after announcing a commercial humanoid-robotics initiative using Unitree G1 robots and facility-management data, reframing the company as a robotics-and-AI data play; the rally comes despite 2025 net loss, dilution risk from a relaunched at-the-market share-sale program, and no disclosed robot-related revenue or contracts.
Gas prices jump again: RBOB gasoline futures spike 6% as Iran conflict tightens supply
Previous Story

Gas prices jump again: RBOB gasoline futures spike 6% as Iran conflict tightens supply

Micron Technology stock week ahead: 6.7% slide puts March 18 earnings and AI demand in focus
Next Story

Micron Technology stock week ahead: 6.7% slide puts March 18 earnings and AI demand in focus

Go toTop